Ruxolitinib is a selective JAK1 and JAK2 inhibitor that also has modest selectivity against tyrosine kinase (TYK) 2 and JAK3 and shows benefit in COVID-19 [89]. This evidence concerns the gene JAK2 and COVID-19.